Endo Pharmaceuticals announced that it has licensed from Grunenthal the exclusive rights to develop and market the investigational drug axomadol in the United States and Canada.
The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.
President Barack Obama's budget aims to foster generic competition for costly biotech drugs used to treat cancer and other intractable ailments.
Abbott announced that it has completed its acquisition of Advanced Medical Optics.
Federal health officials are adding their sternest warning to a heartburn drug that has been linked to muscle spasms.
Genzyme Corporation announced that the US Food and Drug Administration (FDA) has granted marketing approval for Synvisc-One.
ChanTest announced that it has acquired Rockville, Maryland-based Applied Cell Sciences.
New data from two studies demonstrate that ultra-deep sequencing with the Genome Sequencer FLX System from 454 Life Sciences, in combination with traditional methods, may provide a deeper understanding of baseline viral resistance and tropism.
Researchers have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells.
A lawyer representing Nigeria in multi-billion dollar lawsuits against Pfizer said that a settlement is close in the cases stemming from the pharmaceutical giant's 1996 drug trial.
Battelle Ventures, LP, has spun out Hepregen Corporation from the Massachusetts Institute of Technology.
Greenleaf Health LLC announced that Andrew C. von Eschenbach, MD, who recently stepped down as Commissioner of the Food and Drug Administration (FDA), has joined the firm as Senior Advisor.
Researchers from Boston University School of Medicine (BUSM) are encouraging prenatal vitamin manufacturers to use only potassium iodide and not other sources of iodine in their products.
Millipore Corporation announced that it has purchased the assets associated with Epitome Biosystems’ EpiTag technology.
Findings by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.